Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215297 | 0.94 | EPHX1 (0.65) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2026360 | 0.88 | EPHX1 (0.55) | EPHX1HPGDALDH1A1MAPTUSP2 | |
| SCHEMBL556321 | 0.88 | EPHX1 (0.55) | EPHX1HPGDALDH1A1MAPTUSP2 | |
| SCHEMBL2024838 | 0.88 | EPHX1 (0.55) | EPHX1HPGDALDH1A1MAPTUSP2 | |
| SCHEMBL31700886 | 0.84 | EPHX1 (0.55) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL189361 | 0.84 | EPHX1 (0.57) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2380125 | 0.84 | EPHX1 (0.70) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL671402 | 0.84 | EPHX1 (0.57) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2500606 | 0.84 | EPHX1 (0.57) | EPHX1HPGDALDH1A1MAPTL3MBTL1 | |
| SCHEMBL1001758 | 0.84 | EPHX1 (0.75) | EPHX1HPGDALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| WO-2007069053-A1 | BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | EPHX1 600/4885HPGD 1433/4885ALDH1A1 2048/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | EPHX1 995/4885HPGD 1082/4885ALDH1A1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.